Drug
Olutasidenib clinical trials
Also written FT 2102 and Rezlidhia.
Keep track of what changes. Save the olutasidenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 11
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (2) · Rigel Pharmaceuticals (2) · City of Hope Medical Center (1) · University of California, Davis (1) · Timothy Pardee (1) · Kissei Pharmaceutical Co., Ltd. (1) · Justin Watts, MD (1)
Often tested with
Tested in the same studies.
Venetoclax (4) · Azacitidine (3) · Decitabine and cedazuridine drug combination (2) · Ziftomenib (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · CA-4948 (1)
Studies
Open first, then newest update. How each study uses olutasidenib is read from its arms, and is right about nine times in ten.
Testing it · 14
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Olutasidenib
- Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06543381Written as Olutasidenib
- A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid MalignanciesRecruitingPhase 2M.D. Anderson Cancer CenterNCT06668584Written as Olutasidenib
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06445959Written as Olutasidenib
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating AgentRecruitingPhase 2University of California, DavisNCT07304011Written as Olutasidenib
- A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.RecruitingPhase 2M.D. Anderson Cancer CenterNCT06566742Written as Olutasidenib
- Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07153497Written as Olutasidenib
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxRecruitingPhase 2Timothy PardeeNCT07471841Written as Olutasidenib
- Study of Olutasidenib and Temozolomide in HGGRecruitingPhase 2Rigel PharmaceuticalsNCT06161974Written as Olutasidenib + TMZ
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRecruitingPhase 4Rigel PharmaceuticalsNCT07486713Written as Olutasidenib
- A Clinical Trial of Olutasidenib in Patients With Acute Myeloid LeukemiaRecruitingPhase 2Kissei Pharmaceutical Co., Ltd.NCT07604064Written as Olutasidenib
- Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyRecruitingPhase 2Justin Watts, MDNCT06782542Written as Olutasidenib
- A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmWithdrawnPhase 2M.D. Anderson Cancer CenterNCT06597734Written as Olutasidenib
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT07411586Written as Olutasidenib
Given in every arm · 3 — olutasidenib is usual care beside what is tested
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Olutasidenib
- Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationCompletedPhase 1/2Forma Therapeutics, Inc.NCT02719574Written as FT-2102 (olutasidenib)
- A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationCompletedPhase 1/2Forma Therapeutics, Inc.NCT03684811Written as FT-2102
Codes
What other systems call olutasidenib · ClinicalTrials.gg INT001407
- MeSH (NLM) C000710173olutasidenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0T4IMT8S5ZOLUTASIDENIBConfirmed FDA, NLM, Wikidata
- RxNorm 2623641One source FDA
- Wikidata Q76854304olutasidenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C129687OlutasidenibOne source FDA
- DrugBank DB16267One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710173 | olutasidenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0T4IMT8S5Z | OLUTASIDENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2623641 | — | One source FDA |
| Wikidata | Q76854304 | olutasidenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C129687 | Olutasidenib | One source FDA |
| DrugBank | DB16267 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.